Current
Neuro-Oncology


Volume 23 Number 9
May 2021


Home > Publications > Current Neuro-Oncology > Volume 23, Year 2021 > Number 9, May



Contents


Gliomas


High-grade gliomas


Diffuse astrocytic and oligodendroglial tumors


Glioblastoma


○○ Gliosarcoma


Diffuse Midline Glioma


Oligodendroglioma


Meningiomas


Familial tumor syndromes


Metastatic tumors



Gliomas


Gao F, Zhao W, Li M, Ren X, Jiang H, Cui Y, Lin S.
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Biosci Trends. 2021 May 11;15(2):107-117. doi: 10.5582/bst.2021.01017. Epub 2021 Apr 29. PMID: 33952802. Retrospective analysis.




Huang WY, Wen LH, Wu G, Pang PP, Ogbuji R, Zhang CC, Chen F, Zhao JN.
Radiological model based on the standard magnetic resonance sequences for detecting methylguanine methyltransferase methylation in glioma using texture analysis.
Cancer Sci. 2021 May 1. doi: 10.1111/cas.14918. Epub ahead of print. PMID: 33932065. Retrospective analysis.



*

Kheiri G, Habibi Z, Nejat F.
Spontaneous regression of congenital brain tumors: a report of two cases.
Childs Nerv Syst. 2021 May 1. doi: 10.1007/s00381-021-05172-1. Epub ahead of print. PMID: 33934203. Case series;



High-grade gliomas



Lietke S, Schmutzer M, Schwartz C, Weller J, Siller S, Aumiller M, Heckl C, Forbrig R, Niyazi M, Egensperger R, Stepp H, Sroka R, Tonn JC, Rühm A, Thon N.
Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences.
Cancers (Basel). 2021 Apr 7;13(8):1767. doi: 10.3390/cancers13081767. PMID: 33917116. Retrospective analysis.



Diffuse astrocytic and oligodendroglial tumors



Glioblastoma


*

Almengló C, Caamaño P, Fraga M, Devesa J, Costoya JA, Arce VM.
From neural stem cells to glioblastoma: A natural history of GBM recapitulated in vitro.
J Cell Physiol. 2021 May 7. doi: 10.1002/jcp.30409. Epub ahead of print. PMID: 33959982. Laboratory investigation;




Compter I, Verduin M, Shi Z, Woodruff HC, Smeenk RJ, Rozema T, Leijenaar RTH, Monshouwer R, Eekers DBP, Hoeben A, Postma AA, Dekker A, De Ruysscher D, Lambin P, Wee L.
Deciphering the glioblastoma phenotype by computed tomography radiomics.
Radiother Oncol. 2021 May 10;160:132-139. doi: 10.1016/j.radonc.2021.05.002. Epub ahead of print. PMID: 33984349. Retrospecive analysis.




Gangoso E, Southgate B, Bradley L, Rus S, Galvez-Cancino F, McGivern N, Güç E, Kapourani CA, Byron A, Ferguson KM, Alfazema N, Morrison G, Grant V, Blin C, Sou I, Marques-Torrejon MA, Conde L, Parrinello S, Herrero J, Beck S, Brandner S, Brennan PM, Bertone P, Pollard JW, Quezada SA, Sproul D, Frame MC, Serrels A, Pollard SM.
Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.
Cell. 2021 Apr 29;184(9):2454-2470.e26. doi: 10.1016/j.cell.2021.03.023. Epub 2021 Apr 14. PMID: 33857425. Laboratory investigation.



*

Kochanowski P, Catapano J, Pudełek M, Wróbel T, Madeja Z, Ryszawy D, Czyż J.
Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)+ Glioblastoma Cells in a Snail-1/Cx43-Dependent Manner.
Int J Mol Sci. 2021 Apr 16;22(8):4150. doi: 10.3390/ijms22084150. PMID: 33923767. Laboratory investigation.




Kudulaiti N, Zhou Z, Luo C, Zhang J, Zhu F, Wu J.
A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study.
BMC Surg. 2021 May 6;21(1):238. doi: 10.1186/s12893-021-01233-z. PMID: 33957923. Retrospecive analysis.




Li M, Ren X, Dong G, Wang J, Jiang H, Yang C, Zhao X, Zhu Q, Cui Y, Yu K, Lin S.
Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features.
Front Oncol. 2021 Apr 20;11:627325. doi: 10.3389/fonc.2021.627325. PMID: 33959496. Retrospective analysis.




Pasquini L, Napolitano A, Tagliente E, Dellepiane F, Lucignani M, Vidiri A, Ranazzi G, Stoppacciaro A, Moltoni G, Nicolai M, Romano A, Di Napoli A, Bozzao A.
Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM.
J Pers Med. 2021 Apr 9;11(4):290. doi: 10.3390/jpm11040290. PMID: 33918828. Retrospective analysis.




Shim KY, Chung SW, Jeong JH, Hwang I, Park CK, Kim TM, Park SH, Won JK, Lee JH, Lee ST, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH, Choi KS, Choi SH.
Radiomics-based neural network predicts recurrence patterns in glioblastoma using dynamic susceptibility contrast-enhanced MRI.
Sci Rep. 2021 May 11;11(1):9974. doi: 10.1038/s41598-021-89218-z. PMID: 33976264. Retrospective analysis.




Sim HW, McDonald KL, Lwin Z, Barnes EH, Rosenthal M, Foote MC, Koh ES, Back M, Wheeler H, Sulman EP, Buckland ME, Fisher L, Leonard R, Hall M, Ashley DM, Yip S, Simes J, Khasraw M.
A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Neuro Oncol. 2021 May 13:noab111. doi: 10.1093/neuonc/noab111. Epub ahead of print. PMID: 33984151. Phase 2 trial;




Tomei S, Volontè A, Ravindran S, Mazzoleni S, Wang E, Galli R, Maccalli C.
MicroRNA Expression Profile Distinguishes Glioblastoma Stem Cells from Differentiated Tumor Cells.
J Pers Med. 2021 Apr 1;11(4):264. doi: 10.3390/jpm11040264 PMID: 33916317. Laboratory investigation.




Vils A, Bogowicz M, Tanadini-Lang S, Vuong D, Saltybaeva N, Kraft J, Wirsching HG, Gramatzki D, Wick W, Rushing E, Reifenberger G, Guckenberger M, Weller M, Andratschke N.
Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial.
Front Oncol. 2021 Apr 14;11:636672. doi: 10.3389/fonc.2021.636672. PMID: 33937035. Retrospecive analysis.




Zheng L, Zhou ZR, Shi M, Chen H, Yu QQ, Yang Y, Liu L, Zhang L, Guo Y, Zhou X, Li C, Wei Q.
Nomograms for predicting progression-free survival and overall survival after surgery and concurrent chemoradiotherapy for glioblastoma: a retrospective cohort study.
Ann Transl Med. 2021 Apr;9(7):571. doi: 10.21037/atm-21-673. PMID: 33987269. Retrospecive analysis.



Gliosarcoma



Maurer CJ, Mader I, Joachimski F, Staszewski O, Märkl B, Urbach H, Roelz R.
Do gliosarcomas have distinct imaging features on routine MRI?
Neuroradiol J. 2021 Apr 30:19714009211012345. doi: 10.1177/19714009211012345. Epub ahead of print. PMID: 33928823. Retrospective analysis.



Diffuse midline glioma



El-Khouly FE, Veldhuijzen van Zanten SEM, Jansen MHA, Bakker DP, Sanchez Aliaga E, Hendrikse NH, Vandertop WP, van Vuurden DG, Kaspers GJL.
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
J Neurooncol. 2021 May 7
. doi: 10.1007/s11060-021-03763-1. Epub ahead of print. PMID: 33963476. Phase 1-2 trial.




On J, Natsumeda M, Watanabe J, Saito S, Kanemaru Y, Abe H, Tsukamoto Y, Okada M, Oishi M, Yoshimura J, Kakita A, Fujii Y.
Low Detection Rate of H3K27M Mutations in Cerebrospinal Fluid Obtained from Lumbar Puncture in Newly Diagnosed Diffuse Midline Gliomas.
Diagnostics (Basel). 2021 Apr 9;11(4):681. doi: 10.3390/diagnostics11040681. PMID: 33918936. Retrospective analysis.




Tam LT, Yeom KW, Wright JN, Jaju A, Radmanesh A, Han M, Toescu S, Maleki M, Chen E, Campion A, Lai HA, Eghbal AA, Oztekin O, Mankad K, Hargrave D, Jacques TS, Goetti R, Lober RM, Cheshier SH, Napel S, Said M, Aquilina K, Ho CY, Monje M, Vitanza NA, Mattonen SA.
MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study.
Neurooncol Adv. 2021 Mar 5;3(1):vdab042. doi: 10.1093/noajnl/vdab042. PMID: 33977272. Retrospective analysis.




Zamora PL, Miller SR, Kovoor JJ.
Single institution experience in re-irradiation of biopsy-proven diffuse intrinsic pontine gliomas.
Childs Nerv Syst. 2021 May 10. doi: 10.1007/s00381-021-05195-8. Epub ahead of print. PMID: 33973056. Retrospective analysis;



Oligodendroglioma



Cao L, Rong P, Zhu G, Xu A, Chen S.
Clinical Characteristics and Overall Survival Prognostic Nomogram for Oligodendroglioma: A Surveillance, Epidemiology, and End Results Population-Based Analysis.
World Neurosurg. 2021 May 5:S1878-8750(21)00665-3. doi: 10.1016/j.wneu.2021.04.122. Epub ahead of print. PMID: 33964496. Retrospective analysis;



*

Weller J, Katzendobler S, Karschnia P, Lietke S, Egensperger R, Thon N, Weller M, Suchorska B, Tonn JC.
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
J Neurooncol. 2021 May 1. doi: 10.1007/s11060-021-03765-z. Epub ahead of print. PMID: 33932195. Prospective study.



Meningiomas


Kotecha R, Tonse R, Appel H, Odia Y, Kotecha RR, Rabinowits G, Mehta MP.
Regression of Intracranial Meningiomas Following Treatment with Cabozantinib.
Curr Oncol. 2021 Apr 18;28(2):1537-1543. doi: 10.3390/curroncol28020145. PMID: 33919580. Case report.




Vega-Moreno DA, Santellán-Herández JO, Velázquez-Domínguez HE, Martínez-Nava AO, Vicuña-González RM, Mendoza-Trillo PR, Reyes-Rodríguez VA, Ibarra de la-Torre A, González-González IE, Ochoa-Cacique D, Sánchez-Mata R, Molina-Martinez RP, García-González U.
Histopathological correlation (WHO Classification) of meningiomas and their anatomical localization. Multicenter epidemiological study in Mexico.
World Neurosurg. 2021 May 8:S1878-8750(21)00686-0. doi: 10.1016/j.wneu.2021.05.003. Epub ahead of print. PMID: 33974982. Retrospective analysis;



Familial tumor syndromes


Ronsley R, Hounjet CD, Cheng S, Rassekh SR, Duncan WJ, Dunham C, Gardiner J, Ghag A, Ludemann JP, Wensley D, Rehmus W, Sargent MA, Hukin J.
Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
Cancer Med. 2021 Jun;10(11):3556-3564. doi: 10.1002/cam4.3910. Epub 2021 May 3. PMID: 33939292. Case series.



Metastatic tumors


Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Kirschbrown W, Kumthekar P.
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
J Clin Oncol. 2021 May 4:JCO2002822. doi: 10.1200/JCO.20.02822. Epub ahead of print. PMID: 33945296. Phase 2 trial.



bottom

***********************